Yang, Haitang; Shun-Qing, Liang; Schmid, Ralph A.; Peng, Ren-Wang (2019). New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. Frontiers in oncology, 9, p. 953. Frontiers Research Foundation 10.3389/fonc.2019.00953
|
Text
Yang HAITANG 19 FrontOncol KRAS REVIEW.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (2MB) | Preview |
In non-small cell lung cancer (NSCLC), the most frequent oncogenic mutation in western countries is KRAS, for which, however, there remains no clinically approved targeted therapies. Recent progress on high biological heterogeneity including diverse KRAS point mutations, varying dependence on mutant KRAS, wide spectrum of other co-occurring genetic alterations, as well as distinct cellular status across the epithelial-to-mesenchymal transition (EMT), has not only deepened our understanding about the pathobiology of KRAS-mutant NSCLC but also brought about unprecedented new hopes for precision treatment of patients. In this review, we provide an update on the most recent advances in KRAS-mutant lung cancer, with a focus on mechanistic insights into tumor heterogeneity, the potential clinic implications and new therapies on horizons tailored for KRAS-mutant lung cancer.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Thoracic Surgery 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Mu50 > Forschungsgruppe Thoraxchirurgie |
Graduate School: |
Graduate School for Cellular and Biomedical Sciences (GCB) |
UniBE Contributor: |
Yang, Haitang, Shun-Qing, Liang, Schmid, Ralph, Peng, Ren-Wang |
Subjects: |
600 Technology > 610 Medicine & health 500 Science > 570 Life sciences; biology |
ISSN: |
2234-943X |
Publisher: |
Frontiers Research Foundation |
Language: |
English |
Submitter: |
Thomas Michael Marti |
Date Deposited: |
12 Nov 2019 09:41 |
Last Modified: |
05 Dec 2022 15:32 |
Publisher DOI: |
10.3389/fonc.2019.00953 |
PubMed ID: |
31612108 |
Uncontrolled Keywords: |
KRAS heterogeneity immunotherapy lung cancer mitogen-activated protein kinases targeted therapy |
BORIS DOI: |
10.7892/boris.134637 |
URI: |
https://boris.unibe.ch/id/eprint/134637 |
Actions (login required)
 |
Edit item |